Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Thrombosis Stories

2012-02-29 04:00:00

ADDISON, Ill., Feb. 29, 2012 /PRNewswire/ --ArjoHuntleigh is pleased to announce that it has been awarded a three year national contract with Amerinet Choice LLC, the Preferred Portfolio subsidiary of Amerinet, one of the nation's largest group purchasing organizations, as a preferred supplier of vascular compression devices utilized for deep vein thrombosis (DVT) prevention. The agreement, effective January 1, 2012, allows Amerinet members to take advantage of pre-negotiated special pricing...

2012-02-23 08:00:00

According to court documents, on February 15th, 2012, North Dakota resident Donna L. Praus filed a lawsuit (case no. 3:2012cv20009) in the Illinois Southern District Court against Bayer Pharmaceuticals, the company manufacturing Yasmin, claiming that she suffered an alleged deep vein thrombosis (DVT) from taking Yasmin and its similar sister Yaz. Yasmin is a birth control pill that has been on the market since 2001. Last month, as reported by the Washington monthly and BMJ, an advisory...

2012-02-21 06:04:39

(Ivanhoe Newswire)-- Patients who are receiving chemotherapy for cancer are at risk for venous thromboembolism.  Now, researchers show how a new treatment may help. In a double blind study the effectiveness and safety of ultra-low-molecular-weight heparin semuloparin was tested in the prevention of venous thromboembolism in patients with metastatic or locally advanced solid tumors who are just starting to receive chemotherapy. The results showed that venous thromboemeolism occurred...

2012-02-16 11:17:48

For decades, the blood thinner heparin has been used to prevent and treat blood clots. Could it be just as effective in treating cancer? In an editorial published today in the New England Journal of Medicine, researchers from McMaster University and the University at Buffalo suggest conclusive answers to key questions on the benefits of low molecular weight heparin (LMWH) for cancer patients remain elusive - despite promising results from large studies. Co-authors of the editorial are...

2012-02-14 14:14:00

Utah researcher part of panel to develop new guidelines A researcher at Intermountain Medical Center in Salt Lake City is part of a select panel of international experts to help develop new evidence-based clinical guidelines used by physicians worldwide for the diagnosis and treatment of blood-clotting disorders, one of the most common cardiovascular diseases in the United States. Scott M. Stevens, MD, co-director of the Thrombosis Clinic at Intermountain Medical Center, says the new...

2012-02-14 11:40:16

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...

2012-02-14 08:00:00

DENVER, Feb. 14, 2012 /PRNewswire/ -- The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood...

2012-02-14 07:30:00

BEDFORD, Mass., Feb. 14, 2012 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar HIT Assay Panel assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. This fully automated panel includes HemosIL AcuStar HIT-IgG(PF4-H) and HemosIL AcuStar HIT-Ab(PF4-H) assays. (Logo: http://photos.prnewswire.com/prnh/20100803/NE44435LOGO) HemosIL AcuStar HIT assays are the first...

2012-02-07 23:25:48

Anticoagulation therapies may be necessary to prevent blood clots in high-risk patients Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs. However, prolonged use of these therapies may increase the risk of hemorrhage and infection. In the study, "Aspirin was Effective to Prevent Proximal DVT...

2012-02-07 14:40:32

New evidence-based guidelines from the American College of Chest Physicians (ACCP) recommend considering individual patients' risk of thrombosis when deciding for or against the use of preventive therapies for deep vein thrombosis (DVT) and venous thromboembolism (VTE). Specifically, the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, published in the February issue of the journal CHEST, focus on...